Dispatch Bio’s official launch marks a transformative moment in oncology, introducing a novel immunotherapy platform designed to address the longstanding limitations of treating solid tumors. Leveraging its proprietary Flare platform, Dispatch has engineered a universal antigen-based system that uniquely tags solid tumor cells for immune destruction—while dismantling the immune-suppressive microenvironment that has historically undermined immunotherapy effectiveness. This dual-function strategy addresses two of the biggest hurdles in cancer treatment: the absence of universal tumor-specific targets and the formidable resistance of solid tumors to immune cell infiltration and activation.

The Flare platform operates by delivering a viral vector encoding a novel synthetic antigen exclusively expressed by tumor cells, enabling the immune system to precisely identify and attack malignancies without damaging healthy tissue. This approach bypasses the variability and unpredictability of patient-specific biomarkers, offering a scalable, off-the-shelf treatment that could benefit a wide swath of patients across various cancer types. By unifying tumor targeting and immune activation in one modality, Dispatch’s innovation has the potential to produce deep, durable responses that are currently difficult to achieve with existing immunotherapies.

Built on pioneering science from leaders like Carl June, Andy Minn, Chris Garcia, and Kole Roybal, and strengthened through collaboration with the Parker Institute for Cancer Immunotherapy, Dispatch Bio is strategically positioned to redefine cancer therapy. With its mission to pursue a universal cure for solid tumors—a category that accounts for 90% of all cancers—Dispatch is not just addressing a clinical need, but potentially shifting the paradigm for cancer care. As the company advances toward clinical validation, the Flare platform could signal a new era of accessible, targeted, and lasting immunotherapeutic treatments.